Novartis Vaccines & Diagnostics, Gmbh

Novartis Ag

Chiron Corporation

University of Washington

Other

Simon C Ng

Keith Bruce Pfister

Allan S Wagman

Zhi-Jie Ni

Savithri Ramurthy

Marion Wiesmann

Ronald N Zuckermann

Weibo Wang

Sabina Pecchi

Paul Andrew Barsanti

Toni Beth Kline

Reyna J Simon

Eric Harwood

Robert L Warne

Niels H Andersen

Asha Yabannavar

Jason Bowman

Alice L Erwin

Ribhi Shawar

Khisimuzi E Mdluli

Martin Sendzik

James Clifford Sutton

Matthew T Burger

Aaron Matthew Smith

Sharadha Subramanian

Eric J Martin

Yanchen Zhang

Sarah Bartulis

Charles Voliva

Manoj C Desai

Hong Yang

Daniel J Poon

Mark Knapp

Jiong Lan

Mika Lindvall

Wendy Fantl

Teresa E Pick

Elizabeth J Mieuli

Anu Sharma

Victoria Sung

Joelle Verhagen

Gordana Babic Atallah

Johanna M Jansen

Edwin Iwanowicz

Hanne Merritt

Liana M Klivansky

William Lenahan

Susan Kaufman

Thomas Hendrickson

Alicia Louie

Kelly Frazier

Dane A Goff

Paul A Renhowe

Cynthia Shafer

Christopher McBride

Yasheen Zhou

Richard A Goldsmith

Xiaodong Lin

Stephen David Harrison

Amy J Weiner

Timothy D Machajewski

Nicholas M Valiante

Rama Jain

Alice C Rico

Liana Marie Lagniton

Elisa Jazan

Payman Amiri

Nathan Brammeier

Carla C Heise

William R McCrea

Kerry L Spear

Kelly Wayman

Jeffrey H Dove

Mina E Aikawa

Dirksen Bussiere

Lutz Richter

Barbara O Scott

Wei Shu

Jeremy M Murray

Niels H Anderson

Yazhong Pei

Aaron C Sigmund

Charles K Marlowe

Gordana Ataliah

Joel B Silver

Casey Philbin

Anthony Diebes

Hanne Meritt

Xiahua Xin

Xiaohua Xin

Xiaojong M Wang

Stephen E Basham

Aaron Smith

Mika K Lindvall

William P Lenahan

Benzoxazole and benzothiazole compounds and the stereoisomers, tautomers, solvates, oxides, esters, and prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF-1R.

6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. 

Pyrimidine derivatives used as PI-3 kinase inhibitors

Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

CSF-1R inhibitors, compositions, and methods of use

Pyrimidine derivatives used as PI-3-kinase inhibitors

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, autoimmune and cardiovascular diseases.

PI 3-kinase inhibitors and methods of their use

Antibacterial compounds of formula I are provided:  As well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of the compounds.

Antibacterial agents

The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. 

Quinazolines for PDK1 inhibition

New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Pyrrole based inhibitors of glycogen synthase kinase 3

The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.

Thiosemicarbazones as anti-virals and immunopotentiators

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes. 

Benzimidazole quinolinones and uses thereof

Growing community of inventors

Walnut Creek, CA, United States of America

Simon C Ng